Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Patient and provider costs of the new BPaL regimen for drug-resistant tuberculosis treatment in South Africa: A cost-effectiveness analysis

PLoS ONE(2024)10.1371/journal.pone.0309034Source: DataRank Database

Patient and provider costs of the new BPaL regimen for drug-resistant tuberculosis treatment in South Africa: A cost-effectiveness analysis is a research paper published in PLoS ONE (2024). On theSindex it has a DataRank of 0. It has been cited 12 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access12 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 3.92)OA: goldTopics (49)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (14)

Kamban Hirasen ORCID,Clive Ramushu,Lawrence Long ORCID,Edina Sinanovic ORCID,Francesca Conradie ORCID

Live enrichment

PubMed:39432463 PMC:PMC11493257 OpenAlex:https://openalex.org/W4403588079

NIMH NIH HHS

Grant: K01 MH119923

National Institutes of Health

Grant: 5K01MH119923-03

Using behavioral economics to improve the uptake of and persistence on pre-exposure prophylaxis in men who have sex with men to prevent HIV infection

FWCI

3.92

Citation Percentile

0.9%

Citation Trend

2025

2026

goldLicense: cc-by

journalhttps://doi.org/10.1371/journal.pone.0309034

publisherhttps://doi.org/10.1371/journal.pone.0309034

publisherhttps://dx.plos.org/10.1371/journal.pone.0309034

repositoryhttps://pubmed.ncbi.nlm.nih.gov/39432463

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/11493257

Fields of Study

Tuberculosis Research and EpidemiologyHealth Systems, Economic Evaluations, Quality of LifeAntibiotic Use and Resistance0303 health sciences03 medical and health sciences

MeSH Terms

LinezolidCost-Effectiveness AnalysisAdolescentAdultAntitubercular AgentsCost-Benefit AnalysisDrug Therapy, CombinationFemaleHumansMaleMiddle AgedNitroimidazolesSouth AfricaHealth Care CostsTuberculosis, Multidrug-ResistantYoung AdultDiarylquinolines

Keywords

MedicineRegimenBedaquilineTuberculosisHealth careIntensive care medicinePediatricsInternal medicineMycobacterium tuberculosisMaleAdultAdolescentCost-Benefit AnalysisCost-Effectiveness AnalysisAntitubercular AgentsLinezolidHealth Care CostsMiddle AgedSouth AfricaYoung AdultNitroimidazolesTuberculosis, Multidrug-ResistantHumansFemaleDrug Therapy, CombinationDiarylquinolinesResearch Article

Sustainable Development Goals

SDG 0: Good health and well-being